Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Adrian A. Lobito is active.

Publication


Featured researches published by Adrian A. Lobito.


Cell | 1999

Inherited Human Caspase 10 Mutations Underlie Defective Lymphocyte and Dendritic Cell Apoptosis in Autoimmune Lymphoproliferative Syndrome Type II

Jin Wang; Lixin Zheng; Adrian A. Lobito; Francis Ka-Ming Chan; Janet K. Dale; Michael C. Sneller; Xu Yao; Jennifer M. Puck; Stephen E. Straus; Michael J. Lenardo

Caspases are cysteine proteases that mediate programmed cell death in phylogenetically diverse multicellular organisms. We report here two kindreds with autoimmune lymphoproliferative syndrome (ALPS) type II, characterized by abnormal lymphocyte and dendritic cell homeostasis and immune regulatory defects, that harbor independent missense mutations in Caspase 10. These encode amino acid substitutions that decrease caspase activity and interfere with death receptor-induced apoptosis, particularly that stimulated by Fas ligand and TRAIL. These results provide evidence that inherited nonlethal caspase abnormalities cause pleiotropic apoptosis defects underlying autoimmunity in ALPS type II.


European Journal of Immunology | 2000

Inhibition of Fas-mediated apoptosis by the B cell antigen receptor through c-FLIP

Jin Wang; Adrian A. Lobito; Fan Shen; Felicita Hornung; Astar Winoto; Michael J. Lenardo

Cross‐linking of the B cell antigen receptor (BCR) induces resistance to Fas (APO‐1 / CD95)‐dependent apoptosis and thereby regulates one mechanism of B cell selection during antigen stimulation. To investigate the molecular mechanism by which BCR signaling regulates the Fas pathway, we examined the expression of constituents of the death‐inducing signaling complex (DISC), including Fas, FADD, caspase‐8 and cellular FLICE‐inhibitory protein (c‐FLIP). No significant changes in the cellular levels of Fas, FADD or caspase‐8 were observed after BCR cross‐linking. By contrast, the long isoform of c‐FLIP (c‐FLIPL) was significantly up‐regulated by BCR cross‐linking in primary B cells and in two B cell lines, A20 and WEHI‐279. Moreover, transfection of c‐FLIPL into A20 cells inhibited Fas‐dependent apoptosis and suppressed recruitment of caspase‐8 to the DISC. BCR cross‐linking or FLIP overexpression also protects B cells from TRAIL‐induced apoptosis. Thus, BCR signaling up‐regulates c‐FLIPL and suppresses the Fas‐ and TRAIL‐receptor apoptosis pathways which could be important for tolerance and selection of antigen‐specific B cells.


Journal of Cell Biology | 2004

SPOTS signaling protein oligomeric transduction structures are early mediators of death receptor–induced apoptosis at the plasma membrane

Richard M. Siegel; Jagan R. Muppidi; Malabika Sarker; Adrian A. Lobito; Melinda Jen; David A. Martin; Stephen E. Straus; Michael J. Lenardo

Fas (CD95, APO-1, TNFRSF6) is a TNF receptor superfamily member that directly triggers apoptosis and contributes to the maintenance of lymphocyte homeostasis and prevention of autoimmunity. Although FADD and caspase-8 have been identified as key intracellular mediators of Fas signaling, it is not clear how recruitment of these proteins to the Fas death domain leads to activation of caspase-8 in the receptor signaling complex. We have used high-resolution confocal microscopy and live cell imaging to study the sequelae of early events in Fas signaling. These studies have revealed a new stage of Fas signaling in which receptor ligation leads to the formation of surface receptor oligomers that we term signaling protein oligomerization transduction structures (SPOTS). Formation of SPOTS depends on the presence of an intact Fas death domain and FADD but is independent of caspase activity. Analysis of cells expressing Fas mutations from patients with the autoimmune lymphoproliferative syndrome (ALPS) reveals that formation of SPOTS can be disrupted by distinct mechanisms in ALPS.


Proceedings of the National Academy of Sciences of the United States of America | 2010

Concerted action of wild-type and mutant TNF receptors enhances inflammation in TNF receptor 1-associated periodic fever syndrome

Anna Katharina Simon; Heiyoung Park; Ravikanth Maddipati; Adrian A. Lobito; Ariel C. Bulua; Adrianna J. Jackson; Jae Jin Chae; Rachel Ettinger; Heleen D. de Koning; Anthony C. Cruz; Daniel L. Kastner; Hirsh D. Komarow; Richard M. Siegel

TNF, acting through p55 tumor necrosis factor receptor 1 (TNFR1), contributes to the pathogenesis of many inflammatory diseases. TNFR-associated periodic syndrome (TRAPS, OMIM 142680) is an autosomal dominant autoinflammatory disorder characterized by prolonged attacks of fevers, peritonitis, and soft tissue inflammation. TRAPS is caused by missense mutations in the extracellular domain of TNFR1 that affect receptor folding and trafficking. These mutations lead to loss of normal function rather than gain of function, and thus the pathogenesis of TRAPS is an enigma. Here we show that mutant TNFR1 accumulates intracellularly in peripheral blood mononuclear cells of TRAPS patients and in multiple cell types from two independent lines of knockin mice harboring TRAPS-associated TNFR1 mutations. Mutant TNFR1 did not function as a surface receptor for TNF but rather enhanced activation of MAPKs and secretion of proinflammatory cytokines upon stimulation with LPS. Enhanced inflammation depended on autocrine TNF secretion and WT TNFR1 in mouse and human myeloid cells but not in fibroblasts. Heterozygous TNFR1-mutant mice were hypersensitive to LPS-induced septic shock, whereas homozygous TNFR1-mutant mice resembled TNFR1-deficient mice and were resistant to septic shock. Thus WT and mutant TNFR1 act in concert from distinct cellular locations to potentiate inflammation in TRAPS. These findings establish a mechanism of pathogenesis in autosomal dominant diseases where full expression of the disease phenotype depends on functional cooperation between WT and mutant proteins and also may explain partial responses of TRAPS patients to TNF blockade.


Journal of Clinical Investigation | 2007

Dominant-negative effect of the heterozygous C104R TACI mutation in common variable immunodeficiency (CVID)

Lilit Garibyan; Adrian A. Lobito; Richard M. Siegel; Matthew E. Call; Kai W. Wucherpfennig; Raif S. Geha

B cells from patients with common variable immunodeficiency (CVID) who are heterozygous for transmembrane activator and CAML interactor (TACI) mutation C104R, which abolishes ligand binding, fail to produce Igs in response to TACI ligand. It is not known whether this is due to haploinsufficiency or dominant interference. Using in vitro transfection assays, here we demonstrate that C104R and the corresponding murine TACI mutant, C76R, which also does not bind ligand, dominantly interfere with TACI signaling. This effect was dependent on preassociation of the mutants with WT TACI in the absence of ligand. The mutants did not interfere with ligand binding by WT TACI, suggesting that they may act by disrupting ligand-induced receptor rearrangement and signaling. This work demonstrates that TACI preassembles as an oligomeric complex prior to ligand binding and provides a mechanistic insight into how the heterozygous C104R TACI mutation can potentially lead to CVID.


Arthritis Research & Therapy | 2007

Falling into TRAPS – receptor misfolding in the TNF receptor 1-associated periodic fever syndrome

Fiona Clare Kimberley; Adrian A. Lobito; Richard M. Siegel; Gavin Screaton

TNF receptor-associated periodic syndrome (TRAPS) is a dominantly inherited disease caused by missense mutations in the TNF receptor 1 (TNFR1) gene. Patients suffer from periodic bouts of severe abdominal pain, localised inflammation, migratory rashes, and fever. More than 40 individual mutations have been identified, all of which occur in the extracellular domain of TNFR1. In the present review we discuss new findings describing aberrant trafficking and function of TNFR1 harbouring TRAPS mutations, challenging the hypothesis that TRAPS pathology is driven by defective receptor shedding, and we suggest that TNFR1 might acquire novel functions in the endoplasmic reticulum, distinct from its role as a cell surface receptor. We also describe the clinical manifestations of TRAPS, current treatment regimens, and the widening array of patient mutations.


Cell Death & Differentiation | 2006

Homotypic FADD interactions through a conserved RXDLL motif are required for death receptor-induced apoptosis

Jagan R. Muppidi; Adrian A. Lobito; Madhu Ramaswamy; Jin Kuk Yang; Liwei Wang; Hao Wu; Richard M. Siegel

Death receptors in the TNF receptor superfamily signal for apoptosis via the ordered recruitment of FADD and caspase-8 to a death-inducing signaling complex (DISC). However, the nature of the protein–protein interactions in the signaling complex is not well defined. Here we show that FADD self-associates through a conserved RXDLL motif in the death effector domain (DED). Despite exhibiting similar binding to both Fas and caspase-8 and preserved overall secondary structure, FADD RDXLL motif mutants cannot reconstitute FasL- or TRAIL-induced apoptosis and fail to recruit caspase-8 into the DISC of reconstituted FADD-deficient cells. Abolishing self-association can transform FADD into a dominant-negative mutant that interferes with Fas-induced apoptosis and formation of microscopically visible receptor oligomers. These findings suggest that lateral interactions among adapter molecules are required for death receptor apoptosis signaling and implicate self-association into oligomeric assemblies as a key function of death receptor adapter proteins in initiating apoptosis.


Journal of Immunology | 2001

Effective Antigen-Specific Immunotherapy in the Marmoset Model of Multiple Sclerosis

Hugh I. McFarland; Adrian A. Lobito; Michele M. Johnson; Gregory R. Palardy; Christina S.K. Yee; E. Kay Jordan; Joseph A. Frank; Nancy Tresser; Claude P. Genain; John P. Mueller; Louis A. Matis; Michael J. Lenardo

Mature T cells initially respond to Ag by activation and expansion, but high and repeated doses of Ag cause programmed cell death and can suppress T cell-mediated diseases in rodents. We evaluated repeated systemic Ag administration in a marmoset model of experimental allergic encephalomyelitis that closely resembles the human disease multiple sclerosis. We found that treatment with MP4, a chimeric, recombinant polypeptide containing human myelin basic protein and human proteolipid protein epitopes, prevented clinical symptoms and did not exacerbate disease. CNS lesions were also reduced as assessed in vivo by magnetic resonance imaging. Thus, specific Ag-directed therapy can be effective and nontoxic in primates.


Journal of Biological Chemistry | 2011

Murine Insulin Growth Factor-like (IGFL) and Human IGFL1 Proteins Are Induced in Inflammatory Skin Conditions and Bind to a Novel Tumor Necrosis Factor Receptor Family Member, IGFLR1

Adrian A. Lobito; Sree R. Ramani; Irene Tom; J. Fernando Bazan; Elizabeth Luis; Wayne J. Fairbrother; Wenjun Ouyang; Lino C. Gonzalez

Psoriasis is a human skin condition characterized by epidermal hyperproliferation and infiltration of multiple leukocyte populations. In characterizing a novel insulin growth factor (IGF)-like (IGFL) gene in mice (mIGFL), we found transcripts of this gene to be most highly expressed in skin with enhanced expression in models of skin wounding and psoriatic-like inflammation. A possible functional ortholog in humans, IGFL1, was uniquely and significantly induced in psoriatic skin samples. In vitro IGFL1 expression was up-regulated in cultured primary keratinocytes stimulated with tumor necrosis factor α but not by other psoriasis-associated cytokines. Finally, using a secreted and transmembrane protein library, we discovered high affinity interactions between human IGFL1 and mIGFL and the TMEM149 ectodomain. TMEM149 (renamed here as IGFLR1) is an uncharacterized gene with structural similarity to the tumor necrosis factor receptor family. Our studies demonstrate that IGFLR1 is expressed primarily on the surface of mouse T cells. The connection between mIGFL and IGFLR1 receptor suggests mIGFL may influence T cell biology within inflammatory skin conditions.


European Journal of Immunology | 2004

Ectopic T cell receptor expression causes B cell immunodeficiency in transgenic mice.

Adrian A. Lobito; Marcela F. Lopes; Michael J. Lenardo

Mice expressing transgenic T cell receptors (TCR) are used to explore important questions in immunity. However, transgene expression may have unexpected effects. We previously reported a B cell immunodeficiency, comprising decreased B cell numbers and diminished antibody responses, in mice that express a transgenic TCR specific for nicotinic acetylcholine receptor; the mice were generated using cassette vectors designed specifically for transgenic TCR expression [see Kouskoff et al. J. Immunol. Methods 1995. 180: 273–280]. We now show data suggesting that this defect is due to the expression and accumulation of TCR α and β chains inside B cells and induction of an endoplasmic reticulum stress response, causing apoptosis at the pre B‐I and later B cell stage. Thus, inappropriate transgene expression can profoundly affect B cells, leading to a previously undescribed mechanism of immunodeficiency.

Collaboration


Dive into the Adrian A. Lobito's collaboration.

Top Co-Authors

Avatar

Michael J. Lenardo

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Richard M. Siegel

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Jagan R. Muppidi

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Gregory R. Palardy

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Hugh I. McFarland

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Michele M. Johnson

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Daniel L. Kastner

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Hirsh D. Komarow

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Stephen E. Straus

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge